PF-Atlas › Clinical Trials › NCT03092102

The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

HEC585 · Phase 1

Registry ID
NCT03092102
Phase
Phase 1
Status
Completed
Drug / intervention
HEC585
Sponsor
Sunshine Lake Pharma Co., Ltd.
Start
2017-05-20
Enrollment
136
Locations
1

About this trial

The Safety, Tolerability and Pharmacokinetic Study of idiopathic pulmonary fibrosis treatment drug HEC585 in Healthy Male and Female Subjects

View NCT03092102 on ClinicalTrials.gov →

Explore related

All HEC585 trialsAll IPF trials

Related trials

HEC585 — NCT05060822HEC585 — NCT05383131HEC585 — NCT04512170
Medical disclaimer. This page summarizes public trial data for NCT03092102 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.